Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Pancreatic Neoplasms 7Breast Neoplasms 5Radiation Fibrosis Syndrome 3Pancreatic Adenocarcinoma 2Lung Neoplasms 2Glioblastoma 2Thrombocytosis 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neuroma, Acoustic 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 21Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × Losartan × Clear all
NCT03951142 2023-11-01

ImPRESS

Oslo University Hospital

Phase 2 Unknown
165 enrolled
CNS

Brain Neoplasms, Glioblastoma

NCT01805453 2020-05-08

ASTER

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
80 enrolled
CNS

Edema, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡